* BioMarin presented new data in 8 haemophilia A patients with its gene therapy BMN270
* If BM270 eventually reaches the market, it might compete with Baxalta’s haemophilia drugs; but we see major hurdles for it
* No change to our estimates, 5400p target price or Buy rating